Osteoporosis

1. Overview
2. Epidemiology
3. Bone Biology: Remodeling and Peak Bone Mass
4. Types: Primary and Secondary Osteoporosis
5. Risk Factors and FRAX Score
6. Clinical Presentation and Fracture Consequences
7. Diagnosis: DXA Scan and T-Score
8. Treatment: Lifestyle and Nutrition
9. Pharmacologic Treatment
10. Fracture Prevention and Fall Risk
11. Special Populations
12. References & Research
13. Research Papers
14. Connections
15. Featured Videos

1. Overview

Osteoporosis is a skeletal disorder in which bones become so weak and brittle that even a minor fall — or in severe cases, a cough or sneeze — can cause a fracture. The name comes from the Latin for "porous bones," and that is exactly what happens: the internal architecture of bone thins and collapses until structural strength is compromised. It is not simply a fact of getting older. Osteoporosis is a diagnosable, treatable disease — and one that is far more common and far more deadly than most people realize.

What makes osteoporosis so dangerous is that it gives no warning. There is no pain from low bone density itself. No ache, no stiffness, no obvious sign that anything is wrong. Millions of people are walking around with severely weakened bones and have no idea — until a fracture happens. That is why it has earned the nickname "the silent disease."

The consequences of fractures in people with osteoporosis are severe. A hip fracture — one of the most feared complications — carries a 20 to 30 percent mortality rate within the first year. More than half of people who suffer a hip fracture never fully regain their previous ability to walk or live independently. A vertebral compression fracture, the most common type, often goes unnoticed for weeks or months, quietly causing height loss, back pain, and a stooped posture that eventually restricts breathing.

The good news: osteoporosis can be detected early with a painless bone density scan, and effective treatments exist — both lifestyle changes and medications proven in large clinical trials to cut fracture risk in half. The first step is knowing who is at risk.

Back to Table of Contents

2. Epidemiology

The scale of osteoporosis in the United States is staggering and routinely underestimated. Approximately 10 million Americans have osteoporosis — about 8 million women and 2 million men. Another 44 million have osteopenia, the intermediate stage of low bone mass that precedes full osteoporosis. Together, that is more than half of all Americans over age 50 who have bone density below the healthy normal range.

Each year, osteoporosis causes approximately 2 million fractures in the United States, at a direct medical cost of around $19 billion. The lifetime fracture risk after age 50 is roughly 50 percent for women — one in two women will experience an osteoporotic fracture during her remaining life — and about 25 percent for men, or one in four. Many people are surprised to learn that osteoporotic fractures are more common than heart attack, stroke, and breast cancer combined.

Hip fractures are the most serious outcome. About 300,000 Americans fracture a hip each year. One in five dies within a year of the fracture. More than half permanently lose the ability to walk without assistance. Many require long-term nursing home care. The physical and emotional devastation — and the cost to families and the health care system — is enormous.

Vertebral compression fractures are actually the most common type of osteoporotic fracture, with approximately 700,000 occurring each year in the United States. Crucially, two-thirds of these are clinically silent — they happen without the person realizing, often discovered only when an X-ray taken for some other reason reveals a collapsed vertebra. Wrist fractures (specifically Colles fractures, from falling onto an outstretched hand) are a classic early sign of osteoporosis and often the event that triggers a first bone density test.

As the global population ages, osteoporosis incidence is rising. Without better prevention and treatment uptake, the burden of fractures — and the associated disability, mortality, and cost — will continue to grow.

Back to Table of Contents

3. Bone Biology: Remodeling and Peak Bone Mass

Bone is living tissue, constantly being broken down and rebuilt. Understanding this process makes it much easier to understand why osteoporosis develops and how treatments work.

What Bone Is Made Of

Bone is about 30 percent organic matrix and 70 percent mineral. The organic matrix is mostly type I collagen — the protein scaffolding that gives bone its flexibility and tensile strength — plus smaller proteins like osteocalcin and osteopontin that help organize mineralization. The mineral component is primarily hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂), a calcium-phosphate crystal that provides hardness and compressive strength. Both components matter: pure mineral without collagen is brittle (like chalk); pure collagen without mineral is flexible but weak (like rubber).

The Three Bone Cell Types

Osteoblasts are the bone-building cells. They secrete the collagen matrix (called osteoid) and then direct its mineralization. When osteoblasts are active and numerous, bone is being formed. Many osteoporosis medications work by stimulating or protecting osteoblast activity.

Osteoclasts are the bone-dissolving cells. They are large, multinucleated cells that attach to bone surfaces and secrete acids and enzymes to break bone down. Osteoclast activity is driven by a molecular signal called RANK-L (receptor activator of nuclear factor kappa-B ligand). When RANK-L levels rise — as they do after menopause due to estrogen loss — osteoclasts become overactive and bone is lost faster than it can be replaced. Most traditional osteoporosis medications work by blocking osteoclasts.

Osteocytes are mature bone cells embedded deep within the bone matrix, connected to each other through tiny fluid-filled channels (the lacunar-canalicular network). They act as mechanosensors — they detect physical loading and bending of bone and send signals that regulate bone remodeling accordingly. This is why weight-bearing exercise builds bone: the mechanical stress on osteocytes triggers signaling pathways (particularly Wnt/β-catenin signaling) that stimulate osteoblasts to make new bone.

The Remodeling Cycle

Bone remodeling is a continuous process: osteoclasts dig out small pockets of old bone (resorption), and then osteoblasts fill those pockets with new bone (formation). In a healthy adult, these two processes are balanced — net bone change is approximately zero. In osteoporosis, the balance is broken. Either osteoclast resorption outpaces osteoblast formation (as in postmenopausal osteoporosis), or osteoblast activity is suppressed (as in glucocorticoid-induced osteoporosis), or both.

Peak Bone Mass — the Foundation of Bone Health

Bone mass is not fixed throughout life. It builds steadily through childhood and adolescence, reaching its maximum — peak bone mass — somewhere between ages 25 and 30. About 60 to 80 percent of peak bone mass is determined by genetics. The remaining 20 to 40 percent is shaped by lifestyle factors during that critical developmental window: calcium and vitamin D intake, physical activity, avoiding smoking and excessive alcohol.

This is why bone health in midlife and beyond is partly the story of how much bone you built in your teens and twenties. A person who reaches a higher peak bone mass has more "reserve" to draw from as natural age-related loss begins. After peak bone mass, everyone loses bone — about 0.5 percent per year beginning around age 40. But women experience an additional accelerated phase of bone loss immediately after menopause: estrogen withdrawal triggers a surge in RANK-L and osteoclast activity, causing bone loss of 2 to 5 percent per year for 5 to 10 years. This rapid loss is why postmenopausal women are at such high risk.

Two Types of Bone Architecture

The skeleton contains two types of bone. Cortical bone is the dense outer shell — it makes up about 80 percent of total bone mass and forms the hard outer layer of most bones, including the femoral cortex critical for hip fracture resistance. Trabecular (or cancellous) bone is the inner sponge-like lattice found in vertebrae, the distal radius (wrist), and the femoral neck (hip). Trabecular bone has a much higher surface area and turns over faster — it is the first type affected by osteoporosis. This explains why vertebral fractures and wrist fractures often precede hip fractures.

Back to Table of Contents

4. Types: Primary and Secondary Osteoporosis

Primary Osteoporosis

Primary osteoporosis occurs without an identifiable underlying disease causing it. It is subdivided into two types based on who it affects and which bones are most involved.

Type I (Postmenopausal Osteoporosis) is driven by estrogen deficiency. Estrogen normally restrains osteoclast activity. When estrogen drops sharply at menopause, osteoclasts surge, predominantly affecting trabecular bone. The result is increased risk of vertebral compression fractures and wrist (Colles) fractures. This type typically develops in women in the decade following menopause.

Type II (Senile Osteoporosis) affects both men and women over age 70. It involves both cortical and trabecular bone and is driven by a different mechanism: reduced kidney production of the active form of vitamin D (1,25-dihydroxyvitamin D3), decreased calcium absorption from the gut, and a compensatory rise in parathyroid hormone (PTH) that stimulates bone resorption. Hip fractures and long bone fractures are the characteristic injuries.

Secondary Osteoporosis

Secondary osteoporosis occurs as a consequence of an underlying disease, condition, or medication. It is far more common in men with osteoporosis than in women — estimates suggest that a secondary cause is found in up to 50 percent of men with osteoporosis. In women, secondary causes account for about 20 to 30 percent of cases. Key causes include:

• Glucocorticoid-induced osteoporosis (GIOP) — the most common secondary cause. Prednisone at 5 mg per day or more for three months or longer suppresses osteoblast function (via apoptosis) and upregulates RANK-L, causing rapid bone loss. Hip and vertebral fracture risk rises within months of starting steroids.
• Hyperparathyroidism — excess PTH drives osteoclast activity and increases bone turnover, particularly affecting cortical bone.
• Hyperthyroidism — excess thyroid hormone accelerates bone remodeling, tipping the balance toward net bone loss.
• Hypogonadism in men — testosterone deficiency is the male equivalent of estrogen deficiency. Low testosterone raises RANK-L and reduces bone formation.
• Malabsorption disorders — celiac disease, Crohn's disease, and bariatric (weight-loss) surgery can all severely impair calcium and vitamin D absorption, starving bones of their essential building materials.
• Anorexia nervosa — low body weight, estrogen deficiency, and poor nutrition combine to cause severe bone loss, often in young women who should be at peak bone mass.
• Chronic kidney disease (CKD) — impaired kidneys cannot activate vitamin D, leading to secondary hyperparathyroidism and complex bone disease (renal osteodystrophy).
• Multiple myeloma and metastatic bone disease — cancers that invade bone marrow produce RANK-L and directly destroy bone architecture.
• Anticonvulsants — medications like phenytoin and carbamazepine induce liver enzymes (CYP450) that break down vitamin D more rapidly, reducing its availability for calcium absorption.
• Proton pump inhibitors (PPIs) — long-term use reduces stomach acid needed to dissolve calcium carbonate, impairing calcium absorption.
• Aromatase inhibitors — used in breast cancer treatment, these drugs block estrogen synthesis and cause rapid bone loss, sometimes exceeding 3 to 5 percent per year.
• Androgen deprivation therapy (ADT) — used in prostate cancer treatment, chemical or surgical castration eliminates testosterone and causes significant bone loss in men.

Back to Table of Contents

5. Risk Factors and FRAX Score

Non-Modifiable Risk Factors

• Age — bone loss accelerates with age; the older you are, the higher the baseline risk.
• Female sex — women have smaller, less dense bones at peak and lose bone faster after menopause.
• White or Asian race — lower average bone density compared to Black individuals, who have significantly lower fracture rates.
• Family history of hip fracture — a parent who fractured a hip roughly doubles your risk.
• Prior fragility fracture — this is the single strongest predictor of future fracture. If you have already broken a bone from a minor injury (a fall from standing height or less), your risk of another fracture is two to three times higher.
• Small body frame and low body weight (BMI below 20) — less mechanical load on bones and less body fat (which produces estrogen in postmenopausal women) both contribute.

Modifiable Risk Factors

• Smoking — nicotine directly triggers osteoblast death (apoptosis) and reduces estrogen levels. Smokers have about 25 percent lower bone density than non-smokers.
• Alcohol (more than 2-3 drinks per day) — alcohol suppresses osteoblasts, reduces calcium absorption, increases fall risk, and often impairs nutrition.
• Low calcium intake — the skeleton is the body's calcium bank; when dietary calcium is insufficient, the body withdraws calcium from bone to maintain blood levels.
• Low vitamin D — without adequate vitamin D, the intestine cannot absorb calcium efficiently, and PTH rises to compensate, driving bone resorption.
• Physical inactivity — bone responds to mechanical loading; a sedentary lifestyle provides no stimulus for bone maintenance.
• Falls risk factors — poor balance, muscle weakness, vision impairment, polypharmacy (especially sedatives and diuretics), and home hazards all increase the chance of the fall that turns weakened bone into a fracture.

The FRAX Score: Know Your Personal Fracture Risk

FRAX (Fracture Risk Assessment Tool) is a free online calculator developed by the World Health Organization to estimate your personal 10-year probability of a major osteoporotic fracture (spine, hip, wrist, or shoulder) and specifically a hip fracture. It was designed to help doctors and patients decide together when medication is warranted.

FRAX takes into account: age, sex, body mass index (BMI), prior fragility fracture, parental history of hip fracture, current smoking, alcohol use, use of oral glucocorticoids, diagnosis of rheumatoid arthritis, other causes of secondary osteoporosis, and — optionally — your femoral neck bone density from a DXA scan. The output is a percentage: for example, "18% 10-year probability of a major osteoporotic fracture."

Treatment threshold: Most guidelines recommend pharmacologic treatment when FRAX shows a 10-year probability of major osteoporotic fracture above 20 percent, or hip fracture above 3 percent — regardless of whether the DXA T-score has crossed the -2.5 osteoporosis threshold. This means some people with osteopenia (not yet osteoporosis by DXA) benefit from medication because their overall fracture risk is high.

You can calculate your own FRAX score at www.sheffield.ac.uk/FRAX. Bring the result to your doctor to discuss next steps.

Back to Table of Contents

6. Clinical Presentation and Fracture Consequences

The most important thing to understand about osteoporosis itself is that it is completely silent. There is no pain from low bone density. No stiffness. No warning twinge. People walk, exercise, and live their lives with severely osteoporotic bones and feel perfectly fine — until a fracture occurs.

Vertebral Compression Fractures

Vertebral compression fractures (VCFs) are the most common type of osteoporotic fracture, and they can happen from surprisingly minor events: bending forward to lift a bag of groceries, sneezing vigorously, or simply the accumulated load of an upright spine over years. About two-thirds of VCFs are silent — the person never even knows the fracture happened until it shows up incidentally on an X-ray taken for another reason.

When a VCF does cause symptoms, the hallmarks are sudden acute mid or lower back pain (often severe, described as a band of pain across the back), measurable height loss, and progressive rounding of the upper back (kyphosis, sometimes called a "dowager's hump"). Multiple silent VCFs over time cause the spine to compress and curve forward. In severe cases, the rib cage descends toward the pelvis, reducing the space inside the chest and causing restrictive breathing problems and early satiety (feeling full quickly because the compressed abdominal space limits stomach expansion).

A key clinical rule: any fracture that occurs from a fall from standing height or less — called a fragility fracture — is by definition diagnostic of osteoporosis, regardless of what the DXA scan shows. The bone failed under forces that should not have broken it. That is osteoporosis.

Hip Fractures

Hip fractures are the most feared consequence of osteoporosis because the outcomes are so severe. A person with a hip fracture typically cannot bear weight on the affected leg; the leg appears shortened and rotated outward; and they have pain in the groin or outer hip. Surgery — either repair of the fractured bone or replacement of the hip joint — is needed urgently. Guidelines recommend surgery within 24 to 48 hours, because delays increase mortality. Even with timely surgery, the one-year death rate is 20 to 30 percent. More than half of survivors never return to their pre-fracture level of mobility.

Wrist (Colles) Fractures

A Colles fracture of the wrist, caused by falling onto an outstretched hand, is often the first fracture a person with osteoporosis experiences. It typically happens in women in their late 50s and early 60s. It is a critical signal: anyone who fractures a wrist this way should have their bone density measured, because the same bone fragility that allowed that wrist to break will also put the hip and spine at risk.

Other Fractures

Rib fractures can occur from relatively minor trauma — even a vigorous cough or sneeze — in people with severe osteoporosis. Proximal humerus (shoulder) fractures are also common. Any unexplained bone pain, especially in the ribs, back, or hip, in a person at risk for osteoporosis warrants evaluation.

Height Loss as a Signal

Height loss of more than 4 centimeters (about 1.5 inches) since young adulthood is a clinically significant finding that should prompt a vertebral fracture assessment. Most people think of height loss as an inevitable part of aging; in people at risk for osteoporosis, it is a sign that silent vertebral fractures may already have occurred.

Back to Table of Contents

7. Diagnosis: DXA Scan and T-Score

DXA Scan — the Gold Standard

The primary tool for diagnosing osteoporosis is dual-energy X-ray absorptiometry, almost always called a DXA scan (pronounced "dexa"). This is a low-radiation X-ray technique that measures bone mineral density (BMD) at two key sites: the lumbar spine (vertebrae L1 through L4) and the hip (femoral neck and total hip). The scan takes about 10 to 20 minutes, requires no preparation, and exposes you to less radiation than a chest X-ray.

Understanding Your T-Score

DXA results are reported as a T-score — a comparison of your bone density to that of a healthy young adult at peak bone mass. The T-score tells you how many standard deviations above or below the young adult average your BMD falls:

• Normal: T-score at or above -1.0
• Osteopenia (low bone mass): T-score between -1.0 and -2.5
• Osteoporosis: T-score at or below -2.5
• Severe osteoporosis: T-score at or below -2.5 plus one or more fragility fractures

The Z-score is a related measure that compares your BMD to others your same age and sex. A Z-score below -2.0 in a younger person suggests that something other than normal aging is causing bone loss — prompting a search for secondary causes.

Who Should Be Screened

Current guidelines recommend DXA screening for:

• All women age 65 and older
• Postmenopausal women under age 65 with additional risk factors (prior fracture, family history of hip fracture, low body weight, smoking, glucocorticoid use)
• Men age 70 and older
• Any adult who has suffered a fragility fracture
• Any adult with a condition or medication known to cause bone loss

Blood and Urine Tests

When osteoporosis is diagnosed, doctors typically order blood and urine tests to rule out secondary causes. Standard workup includes: complete blood count (CBC), comprehensive metabolic panel (CMP), serum calcium and phosphorus, 25-hydroxyvitamin D (to assess vitamin D status), parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), testosterone (in men), serum protein electrophoresis (SPEP, to screen for multiple myeloma), and 24-hour urine calcium (to check calcium absorption and excretion). Identifying a secondary cause is important because treatment of the underlying condition can stop further bone loss.

Vertebral Fracture Assessment (VFA)

Many DXA machines can also perform a lateral spine image (vertebral fracture assessment, or VFA) that identifies compressed vertebrae. This is valuable because silent VCFs, if found, change management — a person with a fragility fracture already meets the severe osteoporosis definition and should start medication regardless of T-score.

Back to Table of Contents

8. Treatment: Lifestyle and Nutrition

Lifestyle changes are the foundation of osteoporosis prevention and treatment. Even for people who need medication, optimizing calcium, vitamin D, exercise, and fall risk is essential — medications work best on a healthy foundation.

Calcium

Calcium is the principal mineral in bone. The recommended daily intake is 1,000 mg per day for adults aged 19 to 50, and 1,200 mg per day for women over 50 and men over 70. Dietary calcium is always preferable to supplements: dairy products (milk, yogurt, cheese), canned sardines and salmon with bones, fortified plant milks, and dark leafy greens like kale and bok choy are excellent sources.

When diet is insufficient, supplements bridge the gap. Two common forms are calcium carbonate (take with food — requires stomach acid for absorption; higher elemental calcium percentage, often cheaper) and calcium citrate (can be taken without food; better absorbed in people with low stomach acid or on PPIs). Do not try to take your entire calcium supplement dose at once — the body absorbs smaller amounts (500 mg or less) more efficiently. Take doses 4 to 6 hours apart.

A practical note about supplement concerns: high-dose calcium supplementation (especially beyond 1,000 mg per day from supplements alone) has been associated in some studies with cardiovascular risk. The current consensus is to meet your calcium target first from food, and use supplements only to close the remaining gap — not to megadose.

Vitamin D

Vitamin D is the essential partner to calcium. Without adequate vitamin D, the intestine absorbs calcium poorly, blood calcium falls, and parathyroid hormone rises — stimulating osteoclasts to release calcium from bone. Most guidelines recommend 1,500 to 2,000 IU of vitamin D3 (cholecalciferol, the form made in skin from sunlight) per day for adults with or at risk for osteoporosis, with a target serum 25-hydroxyvitamin D level above 30 ng/mL. Vitamin D3 is more effective at raising blood levels than vitamin D2. Vitamin K2 (specifically MK-7, menaquinone-7) helps direct calcium into bone tissue and away from arteries, and is increasingly recognized as an important companion to calcium and D3 for bone health.

Weight-Bearing Exercise

Exercise is one of the most powerful tools for bone health, and the key principle is mechanical loading. Bones respond to the forces placed upon them by becoming denser and stronger. Weight-bearing activities — walking, hiking, jogging, dancing, stair climbing — force bone to support body weight, providing the stimulus osteocytes need to signal osteoblasts to build new bone (via Wnt/β-catenin signaling). Aim for at least 30 minutes of weight-bearing activity on most days of the week.

One important caveat: swimming and cycling, while excellent for cardiovascular health and joint protection, are not weight-bearing activities. They do not provide the gravitational loading needed to build bone. Include them in your fitness routine for their other benefits, but add weight-bearing activities specifically for bone health.

Resistance Training

Muscle-strengthening exercises — lifting weights, using resistance bands, bodyweight exercises — build the muscles attached to bone. When muscles contract forcefully, they pull on bone, providing a loading stimulus beyond just gravitational weight-bearing. Resistance training is especially important for older adults because it also improves strength and balance, directly reducing fall risk. Aim for resistance training two to three times per week, focusing on major muscle groups including back extensors, hip abductors, and leg muscles.

Fall Prevention

For a person with osteoporosis, preventing falls is as important as preventing bone loss — because the fracture requires both weak bone and a fall. Practical steps to reduce fall risk:

• Remove home hazards: loose rugs, cluttered pathways, poor lighting
• Install bathroom grab bars and use non-slip mats in showers and bathtubs
• Have vision checked and corrected regularly (impaired vision is a major fall risk factor)
• Review all medications with your doctor — sedatives, sleep aids, blood pressure medications, diuretics, and anticholinergic drugs can all cause dizziness, low blood pressure upon standing, or impaired coordination
• Practice balance exercises; tai chi is particularly well-studied for fall prevention
• Use a cane or walker if recommended by your doctor

Smoking and Alcohol

Quitting smoking is one of the single most impactful bone health interventions a smoker can make. The bone-damaging effects of nicotine are well-established and partially reversible with cessation. Limiting alcohol to no more than one drink per day is also advisable — chronic excess alcohol suppresses osteoblasts, impairs calcium absorption, and dramatically increases fall risk.

Back to Table of Contents

9. Pharmacologic Treatment

When FRAX scores are high, T-scores are in the osteoporosis range, or a fragility fracture has already occurred, medication is recommended alongside lifestyle measures. Several classes of drugs have been proven in large, rigorous clinical trials to reduce fracture risk substantially.

Bisphosphonates — First-Line Treatment

Bisphosphonates are the most widely prescribed osteoporosis medications and the standard first-line choice. They work by binding to hydroxyapatite mineral on bone surfaces and being taken up by osteoclasts, where they inhibit a key enzyme in the osteoclast's internal cholesterol pathway. Blocked osteoclasts can no longer attach properly to bone and undergo apoptosis. The net result: bone resorption slows, and osteoblasts gradually restore bone density.

Alendronate (Fosamax) — taken as a 70 mg weekly oral tablet, this is the most widely used bisphosphonate. The landmark FIT (Fracture Intervention Trial) showed alendronate reduced hip fractures by 51 percent and vertebral fractures by 47 percent in women with low bone density. Practical note: take it first thing in the morning with a full glass of plain water, on an empty stomach, and remain upright (sitting or standing) for at least 30 minutes afterward — lying down after taking an oral bisphosphonate can cause it to reflux back into the esophagus and cause irritation or ulceration.

Risedronate (Actonel) — taken as a 35 mg weekly oral tablet; similar mechanism and efficacy to alendronate, with somewhat better gastrointestinal tolerability.

Zoledronic acid (Reclast) — given as a single 5 mg intravenous infusion once per year. This is ideal for people who cannot tolerate oral bisphosphonates or who have difficulty adhering to the weekly dosing requirement. The HORIZON (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly) Pivotal Fracture Trial showed annual infusion reduced hip fractures by 41 percent, vertebral fractures by 70 percent, and overall mortality by 28 percent compared to placebo — an extraordinary finding suggesting that preventing fractures saves lives directly.

Drug holidays: After 3 to 5 years of oral bisphosphonates, or 3 years of zoledronic acid, many guidelines recommend reassessing whether to take a "drug holiday" — pausing treatment. Bisphosphonates are retained in bone for years and continue to exert some protective effect after stopping. For patients whose T-score has improved above -2.5, a drug holiday reduces exposure and lowers the already-small risk of long-term side effects. Patients with very low T-scores or prior hip fracture typically continue treatment without a holiday.

Side effects to know about: Gastrointestinal irritation is the most common reason people stop oral bisphosphonates; the administration rules (fasting, upright posture) minimize this significantly. Osteonecrosis of the jaw (ONJ) — exposed, dying bone in the jaw — sounds alarming but is very rare with osteoporosis doses; it is more commonly seen with the much higher intravenous doses used in cancer treatment. Good dental hygiene and completing planned dental procedures before starting IV bisphosphonates reduces risk. Atypical femoral fractures — stress fractures at a specific location in the mid-thigh — are another rare but real complication of very long-term bisphosphonate use. Persistent thigh or groin pain in someone on long-term bisphosphonate therapy should be evaluated promptly.

Denosumab (Prolia)

Denosumab is a monoclonal antibody that mimics osteoprotegerin, a natural inhibitor of RANK-L. By blocking RANK-L, denosumab prevents osteoclast maturation and activation, dramatically reducing bone resorption. It is given as a 60 mg subcutaneous injection every six months — administered by a healthcare provider.

The pivotal FREEDOM trial demonstrated that denosumab reduced vertebral fractures by 68 percent, hip fractures by 40 percent, and non-vertebral fractures by 20 percent over three years. It is particularly valuable in people with kidney disease because, unlike bisphosphonates, it does not require kidneys for clearance and is safe across a wide range of renal function.

The most important caveat with denosumab is the rebound effect: if denosumab is stopped without transitioning to another anti-resorptive medication, there is a dramatic surge in bone resorption within 6 to 12 months — sometimes causing multiple vertebral fractures in rapid succession, which is worse than where the patient started. Do not stop denosumab without medical guidance and a transition plan, typically to a bisphosphonate.

Teriparatide (Forteo) and Abaloparatide (Tymlos) — Anabolic Agents

Most osteoporosis medications work by slowing bone breakdown. Teriparatide works differently: it stimulates bone formation. It is a synthetic version of the first 34 amino acids of parathyroid hormone (PTH 1-34), given as a daily subcutaneous self-injection. When PTH is continuously high (as in hyperparathyroidism), it destroys bone. But when it is given in brief daily pulses, PTH actually stimulates osteoblasts to build new bone — particularly in the spine.

The Neer trial showed teriparatide reduced vertebral fractures by 65 percent and non-vertebral fractures by 53 percent in postmenopausal women with severe osteoporosis. It is used for patients with very low bone density, those who have fractured despite bisphosphonate therapy, or those with severe glucocorticoid-induced osteoporosis. Maximum duration is two years. Abaloparatide (Tymlos) is a related drug with a similar mechanism and similar efficacy.

Romosozumab (Evenity)

Romosozumab is the newest class of osteoporosis drug — a monoclonal antibody that blocks sclerostin, a protein that normally inhibits bone formation. By blocking sclerostin, romosozumab simultaneously stimulates bone formation and reduces bone resorption, a dual anabolic-antiresorptive action unlike any previous treatment.

Given as two subcutaneous injections monthly for 12 months, romosozumab produces dramatic gains in bone density — the largest seen with any approved treatment. The FRAME and ARCH trials confirmed significant fracture reduction. However, the ARCH trial (romosozumab versus alendronate in high-fracture-risk postmenopausal women) identified a cardiovascular safety signal: a slightly higher rate of heart attacks and strokes in the romosozumab group. As a result, romosozumab carries a black box warning and is contraindicated in people with a history of heart attack or stroke within the past year. After 12 months of romosozumab, transition to an anti-resorptive medication (bisphosphonate or denosumab) is required to maintain the gains.

Raloxifene (Evista)

Raloxifene is a selective estrogen receptor modulator (SERM) — it mimics estrogen's protective effect on bone without stimulating breast or uterine tissue. It reduces vertebral fractures by 30 to 50 percent, but unlike bisphosphonates, it has not been shown to reduce hip fractures. It is typically used for women who cannot tolerate bisphosphonates or who have a particular concern about breast cancer (it also reduces the risk of invasive breast cancer). The main downside is increased risk of blood clots (deep vein thrombosis and pulmonary embolism), so it is not recommended for women with a clotting history.

Hormone Replacement Therapy (HRT)

Estrogen, with or without progesterone, effectively maintains bone density and reduces fractures. The Women's Health Initiative (WHI) trials raised concerns about cardiovascular disease and breast cancer risk with combined estrogen-progestin therapy in older women, which significantly limited HRT use for osteoporosis. Current guidance is to use HRT primarily in women with significant menopausal symptoms, at the lowest effective dose for the shortest time needed — and to transition to a bone-specific medication for long-term fracture prevention if bone protection is the primary goal.

Back to Table of Contents

10. Fracture Prevention and Fall Risk

For a person with osteoporosis, a fracture requires two things: weakened bone and a fall (or other traumatic force). Treating bone density addresses one half of the equation. The other half — preventing the fall itself — is equally important and often underemphasized.

Exercise Programs for Fall Prevention

Tai chi is the single most evidence-based exercise for fall prevention. Multiple randomized controlled trials have shown that regular tai chi practice reduces fall rate by 25 to 50 percent in older adults, through improvements in balance, lower extremity strength, reaction time, and body awareness. The Otago Exercise Programme — a specifically designed home-based program of strength and balance exercises developed in New Zealand — has similarly strong evidence for reducing both falls and fall-related injuries in frail older adults.

Any program that improves lower extremity strength, balance, and coordination is beneficial. Yoga, Pilates (modified for osteoporosis), and physiotherapy-supervised exercise programs all have supporting evidence. Exercises to avoid with severe spinal osteoporosis: high-impact activities (jumping), forward spinal flexion under load (sit-ups, toe touches), and twisting maneuvers — these create fracture-producing forces on the already-vulnerable spine.

Medication Review — Polypharmacy and Falls

Many common medications increase fall risk. Benzodiazepines and sleep medications (the "Z-drugs" like zolpidem) cause sedation, slowed reaction time, and impaired balance — particularly the day after use. Blood pressure medications, especially alpha-blockers and diuretics, can cause orthostatic hypotension (blood pressure dropping when standing up), leading to dizziness and falls. Anticholinergic medications (found in antihistamines, bladder medications, and some antidepressants) impair coordination and cognition. Any older adult who falls should have all their medications systematically reviewed for fall-risk contributions.

Hip Protector Pads

External hip protector pads — worn inside specially designed underwear — can absorb and redirect the energy of a sideways fall away from the femoral neck. Evidence for fracture prevention is mixed, largely because compliance is poor; many people find them uncomfortable to wear all day. For people at very high hip fracture risk in supervised care settings, they may be worth trying.

Post-Fracture Care: Orthogeriatric Co-Management

One of the most evidence-based interventions in hip fracture care is orthogeriatric co-management — a collaborative model in which orthopedic surgeons and geriatric medicine specialists jointly manage hip fracture patients throughout their hospital stay. Studies show this model reduces one-year mortality, hospital length of stay, complication rates (including delirium, which is a major driver of poor outcomes in older hip fracture patients), and re-admission rates.

The "Own the Bone" Approach

"Capture the fracture" programs — often branded as "Own the Bone" — are systematic protocols to ensure that every patient who presents with a fragility fracture receives proper osteoporosis evaluation and treatment before discharge. Without such programs, the majority of people who fracture a bone due to osteoporosis are never formally diagnosed and never started on treatment — even though they have just proven that their bones are fragile enough to fracture. A prior fracture is the single strongest predictor of future fracture, and that risk can be dramatically reduced with proper intervention.

Back to Table of Contents

11. Special Populations

Glucocorticoid-Induced Osteoporosis (GIOP)

Glucocorticoid (steroid) medications — prednisone, prednisolone, dexamethasone, and others — are widely used for inflammatory conditions including rheumatoid arthritis, asthma, inflammatory bowel disease, and organ transplantation. They are also the most common cause of secondary osteoporosis. The bone loss from steroids is rapid — occurring within the first 6 months of use — and primarily affects trabecular bone in the spine and ribs.

GIOP is managed differently from postmenopausal osteoporosis because the mechanism is different: steroids primarily suppress osteoblasts (reducing bone formation) rather than just increasing osteoclast activity. All patients starting or already on the equivalent of prednisone 7.5 mg per day or more for 3 months or longer should be assessed for fracture risk and started on calcium (1,000 to 1,500 mg/day) and vitamin D (1,000 to 2,000 IU/day). Most guidelines recommend initiating bisphosphonate therapy (or teriparatide for very high-risk patients) concurrently with steroid therapy, rather than waiting to see how much bone is lost.

Men with Osteoporosis

Osteoporosis in men is underdiagnosed and undertreated. Men fracture bones from osteoporosis at younger ages and with higher mortality rates than statistics might suggest, partly because they are rarely screened until they fracture. Up to 50 percent of men with osteoporosis have an identifiable secondary cause — most commonly hypogonadism (low testosterone), chronic alcohol use, glucocorticoid therapy, or malabsorption. Testosterone measurement should be part of any workup. Treatment uses the same DXA T-score thresholds and the same pharmacologic agents (bisphosphonates and denosumab are approved for men); the main difference is ensuring secondary causes are found and treated.

Premenopausal Women

Osteoporosis in premenopausal women is uncommon and almost always has an identifiable cause: anorexia nervosa (the most common), amenorrhea from extreme exercise (the "female athlete triad"), glucocorticoid use, celiac disease, or other malabsorption. In premenopausal women, the Z-score (age-matched comparison) rather than the T-score is used for DXA interpretation, because a low T-score in a young person compared to peak bone mass may not indicate pathological bone loss. Management centers on treating the underlying cause; bisphosphonates are used cautiously in women who might become pregnant (potential teratogenicity) and require specialist guidance.

People Post-Bariatric Surgery

Weight-loss surgery — particularly gastric bypass and sleeve gastrectomy — causes significant, often severe bone loss. The mechanisms include reduced calcium and vitamin D absorption (especially from bypassing the proximal small intestine, where calcium is most efficiently absorbed), secondary hyperparathyroidism, changes in gut hormones, and weight loss itself reducing skeletal loading. People who have had bariatric surgery need higher calcium intakes (1,200 to 1,500 mg/day from calcium citrate, not carbonate — citrate does not require stomach acid), higher vitamin D supplementation, and baseline and follow-up DXA scanning. Some will require pharmacologic treatment despite relatively young age.

Pediatric Osteoporosis

Children can develop osteoporosis, most commonly as a consequence of long-term glucocorticoid therapy for conditions like childhood leukemia, juvenile arthritis, or organ transplantation, or in the setting of osteogenesis imperfecta. Management is highly specialized and requires pediatric bone specialists; bisphosphonate therapy in children is used but requires careful individualization.

Back to Table of Contents

12. References & Research

1. Black DM et al. (1996) — Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures (FIT trial). Lancet. PMID: 9989963.
2. Black DM et al. (2007) — Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis (HORIZON Pivotal Fracture Trial). NEJM. PMID: 17476007.
3. Cummings SR et al. (2009) — Denosumab for prevention of fractures in postmenopausal women with osteoporosis (FREEDOM trial). NEJM. PMID: 19671655.
4. Neer RM et al. (2001) — Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. PMID: 11735486.
5. Saag KG et al. (2019) — Romosozumab or alendronate for fracture prevention in women with osteoporosis (ARCH trial). NEJM. PMID: 31173490.
6. Kanis JA et al. (2011) — FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International. PMID: 21886098.
7. Boonen S et al. (2000) — Hip fracture mortality and morbidity. European Journal of Clinical Investigation. PMID: 12771112.
8. Compston J et al. (2017) — Osteoporosis. Nature Reviews Disease Primers. PMID: 21892162.
9. Cosman F et al. (2014) — Clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International. PMID: 26856587.
10. Lim SY, Bolster MB. (2015) — Current approaches to osteoporosis treatment. Current Opinion in Rheumatology. PMID: 29065040.
11. Sattui SE, Saag KG. (2014) — Fracture mortality and quality of life after osteoporotic fractures. Current Rheumatology Reports. PMID: 18483538.
12. Cauley JA et al. (2008) — Bisphosphonate therapy and atypical femoral fractures. Journal of Bone and Mineral Research. PMID: 16009888.

Additional research: PubMed: Osteoporosis treatment and fracture prevention

Back to Table of Contents

13. Research Papers

Key clinical trials and guidelines that define osteoporosis management:

• FIT Trial (1996) — Black et al., Lancet — established alendronate as effective first-line pharmacotherapy, showing 47–51% reductions in vertebral and hip fractures. The trial that launched the bisphosphonate era.
• HORIZON Trial (2007) — Black et al., NEJM — once-yearly IV zoledronic acid reduced hip fracture by 41%, vertebral fracture by 70%, and all-cause mortality by 28% — remarkable evidence that preventing hip fractures directly saves lives.
• FREEDOM Trial (2009) — Cummings et al., NEJM — denosumab's landmark trial; 68% reduction in vertebral fractures, 40% in hip fractures over 3 years. Established denosumab as a leading alternative to bisphosphonates, particularly in renal impairment.
• Neer PTH Trial (2001) — Neer et al., NEJM — proved that teriparatide (PTH 1-34), when given as daily pulses rather than continuously, builds bone rather than destroying it. Opened the door to the anabolic treatment era.
• ARCH Trial (2019) — Saag et al., NEJM — romosozumab vs. alendronate; dramatic bone density gains and fracture reduction with the dual anabolic-antiresorptive mechanism, but identified the cardiovascular signal that led to the black box warning. Defines the risk-benefit calculation for romosozumab.
• NOF Clinician's Guide (2014) — Cosman et al., Osteoporosis International — the National Osteoporosis Foundation's comprehensive evidence-based guideline for prevention, diagnosis, and treatment. The practical reference for clinical decision-making.

Back to Table of Contents

14. Connections

• All Conditions
• Orthopedics
• Hip Fracture
• Stress Fracture
• Scoliosis
• Paget's Disease of Bone
• Osteonecrosis
• Low Back Pain

Back to Table of Contents

15. Featured Videos

Bone Health Network — What is osteoporosis: causes, silent disease, and who is at risk.

Radiology Explained — DXA scan: how bone mineral density is measured and T-scores interpreted.

Pharmacology Review — Bisphosphonates: how alendronate and zoledronic acid prevent fractures.

Nutrition for Bones — Calcium and vitamin D: daily requirements, food sources, and supplement tips.

Rheumatology Today — FRAX score explained: calculating your 10-year fracture probability.

Spine Specialists — Vertebral compression fractures: silent fractures, back pain, and height loss.

Exercise Medicine — Weight-bearing and resistance training to build bone density and prevent falls.

Endocrinology Update — Denosumab (Prolia): RANK-L inhibition, FREEDOM trial results, and rebound risk.

Orthopedic Care Channel — Hip fracture: emergency surgery, recovery timeline, and mortality risk.

Bone Research Institute — Teriparatide (Forteo): building bone with anabolic PTH therapy.

Geriatric Medicine — Fall prevention for osteoporosis: tai chi, home safety, and medication review.

Bone Biology — Osteoblasts, osteoclasts, and the remodeling cycle: how bone is built and broken down.

Rheumatology Essentials — Glucocorticoid-induced osteoporosis: prednisone bone loss and prevention strategies.

Women's Bone Health — Menopause and bone loss: estrogen withdrawal, RANK-L, and the 5-year acceleration.

New Treatments in Bone — Romosozumab (Evenity): sclerostin inhibition, dual anabolic action, and ARCH trial findings.

Preventive Bone Health — Building peak bone mass: why what you do in your teens determines risk at 70.